Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate In The Recently Completed Phase 1 Study Of Actimab-A In Combination With CLAG-M For Patients With Relapsed Or Refractory AML
by | Dec 14, 2021 | Extra Jobs | 0 comments
Recent Posts
- Spirit Airlines Gets Second Takeover Bid This Year: What Investors Should Know
- Sidus Space Stock Gains After Q4 Results, Clocks 95% Revenue Growth
- Apple App Store Analysis: This Streaming App Passed Disney+ And Netflix Over The Weekend Thanks To Wrestlemania
- $1000 Invested In Best Buy Co 10 Years Ago Would Be Worth This Much
- Here’s How Much $100 Invested In Activision Blizzard 20 Years Ago Would Be Worth Today
Recent Comments